Pneuma Respiratory, Inc.

Newest generation boosts dosing efficiency and confidence SAN FRANCISCO--(BUSINESS WIRE)-- Pneuma Respiratory, a healthcare company focused on the advancement of inhaled respiratory therapeutics, is attending this week’s 41st Annual J.P. Morgan Healthcare Conference in San Francisco to unveil the latest iteration of its fully digital soft mist inhaler. First introduced in 2018, Pneuma Respiratory’s soft mist technology uses electronic breath actuation to simplify usage and improve delivery efficiency. The digital component delivers high dose confidence and real-time dosage verification to healthcare providers. The latest generation of the device introduces several key features to further improve the efficacy of inhaled therapeutics: Respirable fractions up to 90%. Proprietary new aerosol generation technology produces a higher respirable fraction that significantly improves dosing efficiency and shows potential for lowering the overall dosage to create improved safety pro Voice coaching. Users are walked through the inhalation process in real-time, reducing the potential for misuse and improving patient compliance. High dose confidence. Dosage is measured throughout the administration process. If a patient does not receive the full dose initially, the device calculates the remaining dosage and gives the patient a voice command to inhale again to complete the dosage. Low shearing of biologics. The company has developed low-shear aerosol ejectors to deliver fragile biologics without shearing the molecules. This creates significant opportunities with inhaled biologic treatments for a variety of lung conditions. “With our recent innovations we are seeing real progress in establishing partnerships that will directly impact patient outcomes,” said Eric Hunter, Pneuma Respiratory CEO. About Pneuma Respiratory Founded in 2015, Pneuma Respiratory is a healthcare company based in Boone, North Carolina, with operations in Shenzhen, China. Combining proprietary aerosol generation technology with the precision of digital systems, Pneuma Respiratory created the world’s first fully digital, soft mist inhaler with the potential for multiple therapeutic and non-therapeutic applications. For more information, visit .

Dublin, April 16, 2021 (GLOBE NEWSWIRE) -- The "Global Digital Respiratory Devices Market 2021-2030: Focus on Sensors, Smart Inhalers & Nebulizers, Application, 9 Countries' Data, and Competitive Landscape" report has been added to ResearchAndMarkets.com's offering. The Global Digital Respiratory Devices Market is projected to reach $405.1 million by 2030. The study highlights that the market is set to witness a CAGR of 27.31% between 2021 and 2030. This comprehensive study of the global digital respiratory devices market covers the following: Besides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, end-user analysis, and COVID-19 impact on the market. The study indicates that increasing prevalence of respiratory diseases, increasing adoption of digital technology among individuals, and treatment satisfaction with inhaled therapy among individuals are fueling the growth of the market. The study highlights the various emerging opportunities, such as expansion into the emerging markets and predicting future exacerbations, which can be leveraged by players operating in the market. Scope of the Report The purpose of the study is to enable the reader to gain a holistic view of the Global Digital Respiratory Devices Market. The report constitutes an in-depth analysis of the global digital respiratory devices market, including a thorough analysis of the different end-users. The study also provides exhaustive information on competitive landscape, brand share landscape, market share of the leading players, as well as other vital information with respect to the global digital respiratory devices market. The report considers sensors and apps, and smart inhalers and nebulizers. Key Companies Some of the key players contributing to the Global Digital Respiratory Devices Market include 3M Health Care Limited, Adherium Limited, Amiko Digital Health Limited, AstraZeneca, Boehringer Ingelheim International GmbH, Capsule Technologies, Cognita Labs, Cohero Health, Findair Sp. z. o. o, GlaxoSmithKline plc, Novartis AG, Pneuma Respiratory, Propeller Health, Sensiron AG, and Teva Pharmaceuticals Industries Ltd. Key Questions Answered in this Report How can market intelligence on digital respiratory device add value to an organization's decision-making process? Key Topics Covered: 1 Market Overview1.1 Introduction1.2 Digital Respiratory Devices Market Ecosystem1.3 Assumptions and Limitations 2 Market Dynamics2.1 Impact Analysis2.2 Market Drivers2.2.1 Increasing Prevalence of Respiratory Diseases2.2.2 Increasing Adoption of Digital Technology Among Individuals2.2.3 Treatment Satisfaction with Inhaled Therapy Among Individuals2.3 Market Restraints2.3.1 Issues Related to The Accuracy and Reliability of the Device2.3.2 Availability and High Cost Associated with Digital Respiratory Devices2.4 Market Opportunities2.4.1 Expansion into the Emerging Markets2.4.2 Predicting Future Exacerbations 3 Analysis of COVID-19 Impact on Global Digital Respiratory Devices Market3.1 Impact on Market Size3.1.1 Scenario Comparative Analysis (Pre-COVID-19, During-COVID-19, Post-COVID-19)3.1.2 Regional Impact3.1.2.1 North America3.1.2.2 Europe3.1.2.3 Asia-Pacific3.2 Impact on Digital Respiratory Devices Adoption3.2.1 Short-Term Impact (2-4 Years)3.2.2 Mid-Term Impact (5-8 Years)3.2.3 Long-Term Impact (9-12 Years)3.3 Entry Barrier and Opportunities for New Entrants 4 Competitive Landscape4.1 Key Developments and Strategies4.1.1 Agreements and Collaborations4.1.2 Regulatory and Legal Activities4.1.3 Investments, Funding, and Business Expansion4.1.4 Mergers and Acquisitions4.1.5 Awards and Recognitions4.1.6 Product Launches4.2 Market Share Analysis4.3 Industry Attractiveness4.3.1 Bargaining Power of Suppliers4.3.2 Bargaining Power of Buyer4.3.3 Threat of New Entrants4.3.4 Threat of Substitute Products4.3.5 Intensity of Competitive Rivalry 5 Industry Insights5.1 Opportunity Map Analysis of Smart Inhalers and Nebulizers5.2 Smart Inhaler Value Propositions for Stakeholders5.3 Smart Inhalers and Nebulizers - An Important Element of System for Predicting Disease Worsening in Individuals5.4 Business Models for Digital Respiratory Devices Market 6 Global Digital Respiratory Devices Market (by Product Type)6.1 Sensors and Apps6.2 Smart Inhalers and Nebulizers 7 Global Digital Respiratory Devices Market (by Indication)7.1 Asthma7.2 Chronic Obstructive Pulmonary Disease (COPD) 8 Global Digital Respiratory Devices Market (by Region)8.1 North America8.1.1 U.S.8.1.2 Canada8.2 Europe8.2.1 Germany8.2.2 U.K.8.2.3 France8.2.4 Rest-of-Europe8.3 Asia-Pacific (APAC)8.3.1 Japan8.3.2 China8.3.3 Australia8.3.4 India8.3.5 Rest-of-Asia-Pacific (RoAPAC)8.4 Rest-of-the-World (RoW) 9 Company Profiles9.1 3M Health Care Limited9.1.1 Company Overview9.1.2 Role of 3M Health Care Limited in the Global Digital Respiratory Devices Market9.1.3 Financials9.1.3.1 Key Insights on the Financial Health of the Company9.1.4 SWOT Analysis9.2 Adherium Limited9.2.1 Company Overview9.2.2 Role of Adherium Limited in the Global Digital Respiratory Devices Market.9.2.3 Financials9.2.3.1 Key Insights on the Financial Health of the Company9.2.4 SWOT Analysis9.3 Amiko Digital Health Limited9.3.1 Company Overview9.3.2 Role of Amiko Digital Health Limited in the Global Digital Respiratory Devices Market9.3.3 SWOT Analysis9.4 AstraZeneca plc9.4.1 Company Overview9.4.2 Role of AstraZeneca plc in the Global Digital Respiratory Devices Market9.4.3 Financials9.4.3.1 Key Insights on the Financial Health of the Company9.4.4 SWOT Analysis9.5 Boehringer Ingelheim International GmbH9.5.1 Company overview9.5.2 Role of Boehringer Ingelheim International GmbH in the Global Digital Respiratory Devices Market9.5.3 Financials9.5.3.1 Key Insights on the Financial Health of the Company9.5.4 SWOT Analysis9.6 Capsule Technologies, Inc.9.6.1 Company Overview9.6.2 Role of Capsule Technologies, Inc. in the Global Digital Respiratory Devices Market.9.6.3 SWOT Analysis9.7 Cognita Labs9.7.1 Company Overview9.7.2 Role of Cognita Labs in the Global Digital Respiratory Devices Market9.7.3 SWOT Analysis9.8 Cohero Health9.8.1 Company Overview9.8.2 Role of Cohero Health in the Global Digital Respiratory Devices Market9.8.3 SWOT Analysis9.9 Findair Sp. z. o. o9.9.1 Company Overview9.9.2 Role of Findair Sp. z. o. o in the Global Digital Respiratory Devices Market9.9.3 SWOT Analysis9.1 GlaxoSmithKline plc9.10.1 Company overview9.10.2 Role of GlaxoSmithKline plc in the Global Digital Respiratory Devices Market9.10.3 Financials9.10.3.1 Key Insights on the Financial Health of the Company9.10.4 SWOT Analysis9.11 Novartis AG9.11.1 Company overview9.11.2 Role of Novartis AG in the Global Digital Respiratory Devices Market9.11.3 Financials9.11.3.1 Key Insights on the Financial Health of the Company9.11.4 SWOT Analysis9.12 Pneuma Respiratory, Inc.9.12.1 Company Overview9.12.2 Role of Pneuma Respiratory, Inc. in the Global Digital Respiratory Devices Market9.12.3 SWOT Analysis9.13 Propeller Health9.13.1 Company Overview9.13.2 Role of Propeller Health in the Global Digital Respiratory Devices Market9.13.3 SWOT Analysis9.14 Sensirion AG9.14.1 Company overview9.14.2 Role of Sensirion AG in the Global Digital Respiratory Devices Market9.14.3 Financials9.14.3.1 Key Insights on the Financial Health of the Company9.14.4 SWOT Analysis9.15 Teva Pharmaceuticals Industries Ltd.9.15.1 Company Overview9.15.2 Role of Teva Pharmaceuticals Industries Ltd. in the Global Digital Respiratory Devices Market9.15.3 Financials9.15.3.1 Key Insights on the Financial Health of the Company9.15.4 SWOT Analysis 10 Research Scope and Methodology For more information about this report visit